Biotech
🔥 Half of These Lupus Patients Hit Remission on One Off-the-Shelf Dose
Adicet's off-the-shelf CAR-T put 54% of a small lupus trial into remission on a single dose. Then the stock dropped 22%.
What's new in
Pharmatech
Pharmatech
🔥 A Fatal Childhood Brain Disease Had Zero Treatments. The FDA Just Approved a $3.95 Million One.
The FDA approved Ultragenyx's Fayuvi, the first-ever treatment for Sanfilippo syndrome type A, a fatal childhood brain disease with zero prior options. The one-time gene therapy lists at $3.95 million.
Pharmatech
🔥 Lilly's Triple-G Drug Just Hit 30.3% Weight Loss. Then the FDA Line Moved to 2027.
Lilly's triple-G shot retatrutide hit 30.3% weight loss in Phase 3 — surgery territory. Then the FDA filing slipped to Q1 2027 over manufacturing.
Biotech
🔥 A $425,000 Kidney Drug Just Cleared the FDA — and It Hits Two Targets No One Had Hit at Once
Vera Therapeutics just won FDA accelerated approval for TRUTAKNA, the first dual BAFF/APRIL inhibitor for IgA nephropathy — priced at $425,000 a year. Here's why the two-target bet matters.